Study drug YB-1113 for early loss of ovarian function
Part of Women’s health & pregnancy clinical trials.
This Phase 1 trial tests whether YB-1113 is safe and may help fertility in people with POI (early loss of ovarian function). You may be eligible if you have irregular or absent periods for several months and blood tests suggest POI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and under 40 years old, and want fertility help or pregnancy planning
- Your periods have been very infrequent or absent (oligo/amenorrhea) for at least 4 months
- Your blood tests show POI pattern: FSH is at least 25 IU/L on two tests 4–6 weeks apart
- Your AMH blood test is low (1.0 ng/mL or less)
- Recent blood and urine tests are generally normal (CBC, liver/kidney labs, and urinalysis)
- If you used hormonal birth control before, you’ve been off it long enough (over 3 months after pills or over 6 months after Depo)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women with premature ovarian insufficiency (POI) over time to understand how it affects their health. Researchers will collect samples and track health changes to learn more about the condition and its long-term effects.
This trial tests whether hormone replacement therapy (HRT) helps protect bone health in teenagers with premature ovarian insufficiency (POI). It compares HRT to a placebo and also includes healthy volunteers for comparison.
This trial tests whether an immune-modulating drug can restart ovulation and improve fertility in women whose ovaries stopped working due to autoimmune disease. It is for women ages 18–38 with autoimmune premature ovarian insufficiency and certain antibodies.
This study tests whether umbilical cord stem cells can help restore ovarian function in women with primary ovarian insufficiency (POI)—a condition where the ovaries stop working too early. Participants will receive stem cell injections while continuing their current hormone therapy.
This trial tests whether injecting your own PRP (platelet-rich plasma) into the ovaries can improve ovarian function in some menopausal women. It may help those whose menopause seems less advanced, but not everyone will be eligible based on health and test results.
This study looks at how certain blood markers relate to ovarian function in women with normal ovaries, diminished ovarian reserve (DOR), or primary ovarian insufficiency (POI). It may help doctors better understand these conditions.
Hear when a new POI trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.